Soluble ST2 is a biomarker for cardiovascular mortality related to abnormal glucose metabolism in high-risk subjects by Cardellini, Marina et al.
Vol.:(0123456789) 
Acta Diabetologica 
https://doi.org/10.1007/s00592-018-1230-z
ORIGINAL ARTICLE
Soluble ST2 is a biomarker for cardiovascular mortality related 
to abnormal glucose metabolism in high-risk subjects
Marina Cardellini1,2 · Stefano Rizza1,2 · Viviana Casagrande1 · Iris Cardolini1 · Marta Ballanti1 · Francesca Davato1 · 
Ottavia Porzio3,4 · Maria Paola Canale1 · Jacopo Maria Legramante1 · Maria Mavilio1 · Rossella Menghini1 · 
Eugenio Martelli5 · Alessio Farcomeni6 · Massimo Federici1,2
Received: 10 August 2018 / Accepted: 14 September 2018 
© Springer-Verlag Italia S.r.l., part of Springer Nature 2018
Abstract
Aims Inflammation plays a role in the development and progression of type 2 diabetes macroangiopathy. Interleukin 33 (IL-
33) drives production of Th2-associated cytokines. The soluble form of suppression of tumorigenicity 2 (sST2) acting as a 
decoy receptor blocks IL-33 and tones down Th2 inflammatory response. We investigated the role of sST2 as a predictor of 
CV and all-cause mortality in a cohort of patients affected by established atherosclerotic disease.
Methods 399 patients with atherosclerotic disease from the Tor Vergata Atherosclerosis Registry performed follow-up 
every year by phone interview. The primary endpoint was cardiovascular death and the secondary endpoint was death for 
any other disease.
Results sST2 plasma levels were significantly increased from normal glucose-tolerant patients to patients with history of 
type 2 diabetes (p < 0.00001). Levels of sST2 were significantly correlated with fasting plasma glucose (R = 0.16, p = 0.002), 
HbA1c (R = 0.17, p = 0.002), and HOMA (R = 0.16, p = 0.004). Dividing patients in tertiles of sST2 levels, those belonging 
to the highest tertile showed an increased rate of all-cause and cardiovascular mortality, (all-cause mortality p = 0.045 and 
CVD mortality p = 0.02). A multivariate Cox analysis revealed that sST2 increased the risk in cardiovascular mortality per 
SD by hazard ratio 1.050 (95% CI 1.006–1.097, p = 0.025) after adjustment for age and hs-CRP while it did not significantly 
change the risk for all-cause mortality.
Conclusions High circulating level of sST2 is associated to increased CVD mortality and markers of metabolic dysfunction 
in subjects with atherosclerotic disease.
Keywords Insulin resistance · Inflammation · Diabetes · Cardiovascular disease
Background
Cardiovascular diseases (CVD) are still the leading cause 
of death and disability in type 2 diabetic patients despite the 
huge efforts to prevent and treat them precociously. In these 
patients, cardiovascular events typically occur 14.6 years 
earlier and with greater severity than in individuals without 
diabetes [1, 2]. The enhanced CVD risk and mortality in 
type 2 diabetes are due to greater atherosclerotic plaque bur-
den, higher atheroma volume, and smaller coronary artery 
lumen diameter [3]. Multiple mechanisms underlie the ath-
erogenic process in diabetes such as hyperglycemia, dyslipi-
demia, inflammation, reactive oxygen species, endothelial 
dysfunction, hypercoagulability, and vascular calcification 
[4–7].
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Suppression of tumorigenicity 2 (ST2) is a transmem-
brane receptor expressed mostly on the surface of Th2 
and mast cells, and belongs to the Toll-like/IL-1 receptor 
superfamily. In 2005, Schmitz uncovered the ligand for 
ST2, interleukin-33 (IL-33), a cytokine involved in Th2-
dependent inflammatory processes [8]. The binding of IL-33 
to its receptor determines phosphorylation of extracellular 
signal-regulated kinase (ERK) 1/2, p38 MAPK, JNKs and 
activation of NF-κB [9]. The soluble form of ST2 (sST2) is 
generated by alternative splicing and acts as a decoy recep-
tor, and is implicated in the attenuation of the Th2 inflamma-
tory response [10]. The IL33–ST2 pathway was implicated 
in several inflammatory diseases such as asthma, rheuma-
toid arthritis, sepsis, autoimmune, fibro-proliferative and 
cardiovascular diseases [11–13]. IL-33/ST2L signaling has 
cardioprotective effects; it preserves the myocardium against 
hypertrophy and cardiac fibrosis following pressure overload 
[14]. sST2 blocks the binding of IL-33 to his transmembrane 
receptor and the sequent cardioprotective cascade of events.
In the last decade, several evidences allowed to consider 
sST2 as a biomarker and predictor in CVD. Its role in acute 
and chronic heart failure is well demonstrated in numerous 
studies [15–19] enough to induce the FDA to authorize it 
for clinical use and the American College of Cardiology/
American Heart Association to insert it in the update of HF 
guidelines in 2017 [20].
The aim of our study is to investigate the role of sST2 as a 
predictor of CV mortality and all-cause mortality in a cohort 
of patients affected by established atherosclerotic disease 
and its association with glucose tolerance.
Methods
Description of patients
The Tor Vergata Atherosclerosis Registry (TVAR) 
(ISRCTN42405215) was previously described [21]. Here, 
we show a secondary analysis based on follow-up performed 
in 2017. The data were available for 399 subjects for an 
average follow-up of 75 months, 6 patients did not answer 
to follow-up, and 85 patients had missing data on sST2 lev-
els because of no serum available; however, these subjects 
had clinical characteristics similar to those included in the 
analysis.
At recruitment, all patients underwent thorough medical 
history, clinical examination and anthropometric measure-
ments. Patients without history of type 2 diabetes (n = 325) 
performed an oral glucose tolerance test (OGTT) with 75 g 
of glucose. Patients were classified as normal glucose toler-
ant (NGT), impaired glucose tolerant (IGT) or type 2 dia-
betic patients followed ADA classification [22].
Informed consent and ethics committee approval
An informed written consent was obtained from all partici-
pants. The study was approved by the local ethics committee 
and the reported investigations were carried out in accord-
ance with the principles of the Declaration of Helsinki as 
revised in 2000.
Laboratory measurements
Soluble ST2 was detected by double measurements in one 
batch by Quantikine ELISA—Human ST2/IL-1 R4 Immu-
noassay according to manufacturer’s instructions (Cat. Num. 
DST200—R&D Systems, Inc.); the average intra-assay coef-
ficient of variation was 5.6% and interassay coefficient of 
variation was 17.3%. Other laboratory measurements were 
previously described [21]. GFR was estimated with the 
MDRD formula.
Statistical analysis
Baseline parameters were reported as mean and standard 
deviation (SD) for continuous variables and frequencies, and 
percentages for categorical ones. Differences among groups 
were analyzed by one-way ANOVA with Hochberg post hoc 
analysis and χ2 test. Association between continuous vari-
ables was assessed by means of Spearman and partial cor-
relation. Time-to-event data were analyzed by means of log 
rank test or univariate Cox models for categorical or con-
tinuous variables, respectively. Univariate and multivariate 
Cox models were also evaluated, to assess the effect of ST2 
after adjusting for potential confounders. The final multivari-
able Cox model was chosen with forward stepwise regres-
sion based on Akaike Information Criterion (AIC), which 
guarantees a final parsimonious model with best prediction 
performance. All potential predictors were considered for 
final inclusion in the multivariable Cox model.
p values < 0.05 were considered as statistically signifi-
cant. All analysis was performed with IBM software SPSS 
Version 23 (SPSS, Inc., Chicago, IL, USA) and R version 
3.4.2 (Vienna, Austria).
Results
Patient clinical characteristics and impaired glucose 
metabolism
We divided the 399 patients on the basis of the status 
of glucose tolerance: 118 were NGT, 138 IGT, 69 had a 
new diagnosis of type 2 diabetes (neoT2D) and 74 were 
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diabetic (oldT2D) at enrollment, as shown in Table 1. The 
four groups did not differ for age, sex or BMI. As expected 
oldT2D patients showed significantly higher levels of fast-
ing plasma glucose and insulin (p < 0.000001), HbA1c 
(p < 0.000001) and were more insulin resistant (HOMA, 
p < 0.000001). The oldT2D group had a slight reduction 
of the glomerular filtration rate (p = 0.014) and lower lev-
els of LDL cholesterol (p < 0.000001) and triglycerides 
(p = 0.05), probably due to a higher assumption of lipid-
lowering therapies compared with the other groups, as 
shown in Table 1.
Among all the several cytokines and inflammatory mark-
ers evaluated, we found that sST2 plasma levels were sig-
nificantly increased in oldT2D compared with the three 
other groups (ANOVA p < 0.00001, Fig. 1a, post hoc Hoch-
berg analysis NGT vs oldT2D p < 0.001, IGT vs oldT2D 
p < 0.00001, newT2D vs oldT2D p < 0.001), and the 
difference remained significant after adjustment for age and 
GFR (p < 0.00001).
Soluble ST2 and impaired glucose metabolism
We observed that sST2 levels were positively correlated 
with age (R = 0.23, p < 0.0001) and negatively with GFR 
(R = − 0.20, p < 0.0001); no correlations were found with 
BMI, lipid profile, liver function and inflammatory markers 
(hs-CRP, fibrinogen, TNF-α, white blood cells).
The soluble receptor of IL33 was positively corre-
lated with parameters of glucose metabolism such as fast-
ing plasma glucose (R = 0.16, p = 0.002), HbA1c levels 
(R = 0.17, p = 0.002) and HOMA (R = 0.16, p = 0.004) after 
adjustment for age, gender and GFR, as shown in Fig. 1b–d.
We then stratified our cohort according to tertiles of sST2 
levels and we found that patients belonging to the highest 
Table 1  Clinical and biochemical parameters of patients divided on the basis of the degree of glucose impairment
NGT IGT neoT2D oldT2D p
118 138 69 74
Gender (M/W) 89/29 108/30 50/19 50/24 0.377
Age (years) 70.06 ± 9.23 71.72 ± 7.39 71.01 ± 8.61 70.96 ± 7.89 0.466
BMI (kg/m2) 25.91 ± 4.42 26.36 ± 3.90 26.91 ± 3.84 26.73 ± 3.90 0.373
Systolic blood pressure (mmHg) 139.1 ± 22.6 136.3 ± 18.0 137.1 ± 16.8 141.1 ± 18.7 0.405
Diastolic blood pressure (mmHg) 82.72 ± 9.39 80.04 ± 9.62 78.36 ± 9.66 77.53 ± 7.84 0.002
Total cholesterol (mg/dl) 191.8 ± 41.2 184.0 ± 48.6 191.03 ± 42.8 161.3 ± 48.3 0.00001
HDL cholesterol (mg/dl) 46.21 ± 13.41 42.28 ± 13.57 44.06 ± 13.23 41.94 ± 14.65 0.09
LDL cholesterol (mg/dl) 119.12 ± 36.67 114.25 ± 39.91 115.58 ± 38.06 90.93 ± 33.03 0.000001
Triglycerides (mg/dl) 131.26 ± 60.08 157.74 ± 112.30 182.30 ± 220.87 175.84 ± 145.07 0.046
eGFR 78.05 ± 23.93 82.20 ± 25.90 83.06 ± 40.15 69.48 ± 27.07 0.014
AST (UI/l) 20.43 ± 11.40 19.48 ± 8.11 19.94 ± 7.92 18.58 ± 15.34 0.716
ALT (UI/l) 21.36 ± 15.80 21.53 ± 10.23 25.26 ± 12.88 27.64 ± 21.11 0.011
Fasting plasma glucose (mg/dl) 96.3 ± 9.92 98.22 ± 10.30 113.83 ± 19.79 140.81 ± 45.42 < 0.000001
2 h post-load glucose (mg/dl), n = 325 116.63 ± 17.62 167.61 ± 16.99 234.78 ± 34.15 < 0.000001
Fasting plasma insulin (uU/ml) 10.06 ± 7.58 12.25 ± 8.55 18.07 ± 23.56 17.75 ± 15.12 0.0001
2 h post-load plasma insulin (uU/ml), n = 325 59.99 ± 45.76 115.70 ± 81.57 164.85 ± 164.82 < 0.000001
HbA1c (mmol/mol) 37.86 ± 3.47 37.706 ± 4.82 42.21 ± 5.70 54.04 ± 11.66 < 0.000001
HOMA index 2.46 ± 2.14 3.03 ± 2.34 5.24 ± 6.58 7.07 ± 6.53 < 0.000001
hs-CRP (mg/dl) 4.08 ± 6.14 5.01 ± 10.73 7.07 ± 20.15 1.01 ± 1.58 0.023
Fibrinogen (mg/dl) 366.8 ± 95.45 406.2 ± 498.2 369.1 ± 94.25 404.9 ± 126.83 0.684
WBC 6901.1 ± 2010.8 6892.3 ± 1899.5 7438.6 ± 2635.8 7416.4 ± 1817.4 0.115
Statins (n/y), % 49.1/50.9 42.3/57.7 45.5/54.5 20/80 0.001
Fibrates (n/y), % 98.8/1.2 98.1/1.9 97.9/2.1 97.2/2.8 0.936
ASA (n/y), % 37.1/62.9 43.9/56.1 43.5/56.5 42.6/57.4 0.74
ACE-i (n/y), % 67.6/32.4 59.7/40.3 64.5/35.5 50.7/49.3 0.86
ATII RB (n/y), % 71/29 66.1/33.9 68.3/31.7 66.2/33.8 0.86
CCB (n/y), % 65.2/34.8 67.7/32.3 59.1/40.9 54.9/45.1 0.275
B blockers (n/y), % 71.4/28.6 73.1/26.9 75.8/24.2 57.7/42.3 0.077
A blockers (n/y), % 81.9/18.1 91.1/8.9 84.1/15.9 85.1/14.9 0.219
Diuretics (n/y), % 61.6/38.4 66.9/33.1 57.6/42.4 60.9/39.1 0.202
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tertile (sST2 24.18±7.39 ng/ml) were significantly older 
(p = 0.0001) and showed lower levels of total (p < 0.0001) 
and LDL cholesterol (p < 0.0001), a worse kidney function 
measured by GFR (p = 0.03) and higher fasting plasma glu-
cose (p = 0.05), HbA1c levels (p < 0.001) and HOMA index 
(p = 0.05) as shown in Table 2.
Results from follow‑up
399 patients from our cohort participate to annual follow-
up for 74.98 ± 36.27 months. During this period, 99 deaths 
occurred (24.8%) of which 32 (8%) due to cardiovascular 
diseases. We did not find significantly differences in all-
cause mortality and CVD mortality among the four catego-
ries of impaired glucose metabolism.
A Mantel–Cox analysis revealed that patients belonging 
to the highest tertile of sST2 displayed an increased rate of 
all-cause and cardiovascular mortality, as shown in Fig. 2 
(all-cause mortality, log rank test, p = 0.045 and CVD mor-
tality log rank test, p = 0.02).
Among the several parameters and biochemical variables 
available, sIL6R, TNFa, sVCAM, sICAM, ADMA, only age, 
sST2 and hs-CRP were found independently associated with 
all-cause and cardiovascular mortality with univariate Cox 
analysis, as shown in Table 3.
On the basis of these results, we performed a multivariate 
Cox analysis and we observed that sST2, included as contin-
uous variable, increased the risk in cardiovascular mortality 
per SD by hazard ratio 1.050 [95% confidence interval (CI) 
1.006–1.097, p = 0.025] after adjustment for age and hs-CRP 
(Table 4), while it did not significantly change the risk for 
all-cause mortality.
Discussion
In this study, we evaluated whether sST2 may predict all 
cause and CVD-mortality and its links with glucose toler-
ance in a cohort with established atherosclerotic vascu-
lar disease in secondary prevention. Our results revealed 
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Fig. 1  Correlations of sST2 with glucose tolerance status and meta-
bolic variables. a sST2 levels according to glucose tolerance status 
ANOVA p < 0.00001, post hoc Hochberg analysis NGT vs oldT2D 
p < 0.001, IGT vs oldT2D p < 0.00001, newT2D vs oldT2D p < 0.004 
after adjustment for age and GFR (p < 0.00001); b correlation of 
sST2 with fasting plasma glucose levels (partial correlation R = 0.16, 
p = 0.002, after adjustment for age, gender and GFR); c correlation 
of sST2 with HbA1c levels (partial correlation R = 0.17, p = 0.002, 
after adjustment for age, gender and GFR); d correlation of sST2 with 
HOMA-IR (partial correlation R = 0.16, p = 0.004, after adjustment 
for age, gender and GFR)
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Table 2  Clinical and biochemical characteristics of patients divided in tertiles of plasma sST2
Low sST2 Medium sST2 High sST2 p
134 133 132
Age (years) 68.97 ± 8.29 70.35 ± 8.05 73.61 ± 7.82 0.0001
BMI (kg/m2) 26.61 ± 4.14 26.54 ± 3.98 25.99 ± 4.04 0.415
Systolic blood pressure (mmHg) 137.46 ± 20.17 136.4 ± 17.86 140.42 ± 20.24 0.263
Diastolic blood pressure (mmHg) 81.09 ± 10.13 80.39 ± 9.46 78.95 ± 8.63 0.203
Total cholesterol (mg/dl) 194.30 ± 51.32 184.06 ± 40.17 171.7 ± 45.06 0.0004
HDL cholesterol (mg/dl) 43.24 ± 12.96 42.93 ± 14.01 44.90 ± 14.22 0.464
LDL cholesterol (mg/dl) 120.62 ± 42.71 112.64 ± 34.78 101.95 ± 35.74 0.0004
Triglycerides (mg/dl) 153.86 ± 114.22 163.74 ± 120.90 155.30 ± 164.56 0.817
eGFR 82.63 ± 24.35 80.26 ± 24.35 73.49 ± 36.04 0.038
AST (UI/l) 18.72 ± 5.04 20.35 ± 12.60 19.86 ± 12.66 0.474
ALT (UI/l) 20.94 ± 8.51 23.66 ± 16.72 25.33 ± 17.41 0.063
Fasting plasma glucose (mg/dl) 103.13 ± 22.27 109.65 ± 28.44 110.77 ± 30.82 0.05
2 h post-load glucose (mg/dl), n = 325 155.00 ± 44.18 172.04 ± 52.92 170.14 ± 46.88 0.014
Fasting plasma insulin (uU/ml) 11.61 ± 6.73 14.83 ± 20.48 14.18 ± 10.87 0.145
2 h post-load plasma insulin (uU/ml), n = 325 95.12 ± 86.64 117.53 ± 120.42 112.71 ± 108.84 0.239
HbA1c (mmol/mol) 39.41 ± 6.03 42.46 ± 9.73 42.47 ± 9.97 0.006
HOMA index 3.06 ± 2.07 4.16 ± 5.88 4.32 ± 4.68 0.05
hs-CRP 4.01 ± 7.49 4.35 ± 8.15 4.99 ± 16.34 0.79
Fibrinogen 345.2 ± 77.4 376.8 ± 107.18 44.329 ± 513.6 0.032
WBC 6954.8 ± 1819.6 7443.6 ± 2212.1 7086.3 ± 2068.9 0.049
Statins (n/y), % 46.5/53.5 42.9/57.1 32.8/67.2 0.072
Fibrates (n/y), % 99.1/0.9 97.8/2.2 97.4/2.6 0.659
ASA (n/y), % 37.1/62.9 44.7/55.3 43.3/56.7 0.439
ACE-i (n/y), % 63.7/36.3 58.3/40.3 61.3/38.7 0.595
ATII RB (n/y), % 70.2/29.8 61.7/38.3 71.5/28.5 0.218
CCB (n/y), % 73.8/26.2 54.4/45.6 60.5/39.5 0.004
B blockers (n/y), % 66.2/33.8 67.2/32.8 77.4/22.6 0.098
A blockers (n/y), % 83.9/16.1 84.3/15.7 90/10 0.312
Diuretics (n/y), % 70.8/29.2 57.6/42.4 54/46 0.015
Fig. 2  All cause and cardio-
vascular mortality according 
to sST2 tertiles. Mantel–Cox 
analysis showed that the sST2 
highest tertile was significantly 
associated with all cause (a, 
p < 0.04) and cardiovascular 
mortality (b, p < 0.02)
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that increased sST2 is associated with insulin resistance 
and impaired glucose tolerance. The ST2-IL33 pathway is 
involved in several chronic inflammatory conditions such 
as atherosclerosis, obesity and metabolism impairment. 
In genetically obese diabetic (ob/ob) mice, the adminis-
tration of recombinant IL-33 reduced adiposity, fasting 
glucose and improved glucose and insulin tolerance [23]. 
Furthermore, the selective depletion of fat-resident regu-
latory T cells via anti-ST2 antibody treatment increased 
adipose tissue insulin sensitivity in mice [24]. In 2012, 
Miller and colleagues found in a general population that 
only fasting plasma glucose, but not insulin resistance, 
was significantly correlated with ST2 after adjustment for 
age and sex [25]. Previously another study in 158 subjects 
revealed that patients with type 2 diabetes exhibited higher 
sST2 levels compared to healthy controls [26].
We also found that elevated levels of sST2 are asso-
ciated with increased CVD mortality in our secondary 
prevention cohort. The role of this decoy receptor as a 
prognostic biomarker in heart failure is actually well 
recognized [16–19, 27]. The IL-33–ST2L signaling 
showed cardioprotective effects: in experimental models, 
it reduced myocardial fibrosis, prevented cardiomyocyte 
hypertrophy and improved myocardial function [28, 29]. 
The IL-33–ST2 pathway is also involved in the athero-
sclerotic process since IL-33 determined a reduction in 
aortic atherosclerotic plaque formation and, conversely, 
sST2 resulted in development of significantly larger ath-
erosclerotic plaque and increased Th1 response in ApoE 
−/− mice [30]. In our study, all patients suffered from 
chronic atherosclerotic disease and those with higher lev-
els of sST2 showed an increased CVD mortality at follow-
up. To our knowledge, this is the first study demonstrating 
the possible role for sST2 as a predictor for a second fatal 
CV event in a high-risk population.
Table 3  Univariate Cox analysis for all-cause and cardiovascular mortality
All cause mortality CVD mortality
HD 5% 95% p HD 5% 95% p
Gender 0.782 0.483 1.266 0.317 Gender 0.659 0.271 1.602 0.357
Age 1.070 1.039 1.102 0.000 Age 1.130 1.068 1.195 0.000
Diabetes status 1.109 0.913 1.346 0.297 Diabetes status 1.197 0.854 1.678 0.297
Family history of diabetes 0.788 0.491 1.264 0.323 Family history of diabetes 0.683 0.294 1.585 0.374
Family history of CVD 0.554 0.361 0.851 0.007 Family history of CVD 0.430 0.198 0.935 0.033
Smoking 1.269 0.828 1.946 0.274 Smoking 0.951 0.432 2.091 0.900
BMI 0.988 0.939 1.040 0.647 BMI 0.957 0.869 1.055 0.378
Hypertension 1.165 0.636 2.136 0.621 Hypertension 0.921 0.354 2.394 0.866
Statin intake 0.631 0.423 0.943 0.024 Statin intake 0.780 0.390 1.563 0.484
HDL 0.992 0.977 1.008 0.313 HDL 0.996 0.970 1.023 0.787
LDL 1.002 0.997 1.007 0.408 LDL 1.002 0.993 1.011 0.657
Tryglicerides 0.999 0.997 1.001 0.464 Tryglicerides 1.000 0.997 1.003 0.814
AST 1.007 0.991 1.024 0.387 AST 0.992 0.952 1.034 0.713
ALT 0.994 0.976 1.012 0.508 ALT 0.990 0.956 1.024 0.553
GFR 0.988 0.978 0.997 0.008 GFR 0.980 0.964 0.997 0.018
Fasting plasma glucose 1.004 0.998 1.010 0.184 Fasting plasma glucose 1.001 0.988 1.014 0.866
Fasting plasma insulin 0.994 0.974 1.014 0.545 Fasting plasma insulin 1.000 0.974 1.028 0.973
HbA1c 1.011 0.988 1.034 0.363 HbA1c 1.020 0.982 1.060 0.307
hsPCR 1.016 1.005 1.027 0.003 hsPCR 1.021 1.005 1.037 0.009
Fibrinogen 1.000 1.000 1.001 0.413 Fibrinogen 1.000 1.000 1.001 0.416
ST2 1.027 1.002 1.052 0.032 st2 1.052 1.015 1.091 0.006
Table 4  Multivariate cox analysis for all-cause and cardiovascular 
mortality
HR 5% 95% p
Cardiovascular mortality
 sST2 1.050 1.006 1.097 0.0256
 Age 1.139 1.069 1.214 0.0001
 hsPCR 1.018 1.003 1.033 0.0204
All-cause mortality
 sST2 1.018 0.985 1.052 0.284
 Age 1.048 1.011 1.086 0.0107
 hsPCR 1.010 0.997 1.023 0.124
 GFR 0.993 0.983 1.004 0.214
 Statin intake 0.663 0.403 0.994 0.046
 Family history of CVD 0.557 0.358 0.930 0.024
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Our study has some limitations. First, we did not observe 
a specific effect of sST2 on cardiovascular mortality in sub-
jects with impaired glucose metabolism. Given that sST2 
levels correlated with insulin resistance, we can hypothesize 
that the neutral result on mortality in subjects of diabetes 
may be explained by the sample size that we analyzed. Sec-
ond, our study observed a correlation between sST2 and 
GFR but we cannot ascertain whether the increase in the 
first is explained by the latter or vice versa sST2 may affect 
kidney function.
In conclusion, our study is suggestive for a role of sST2 
in deterioration of cardiovascular function in subjects at high 
risk.
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